Congo began administering Ebola vaccinations to healthcare staff in Bunia on Saturday, targeting front-line workers in the epicenter of the fastest-growing outbreak of the disease in history, according to provincial health authorities. The campaign utilizes the Ervebo vaccine under a compassionate-use program as officials contend with a transmission cycle driven by the Bundibugyo virus strain.
Ebola Vaccination Rollout Targets Front-Line Workers in Bunia
Health authorities launched the vaccination drive in the Bunia and Mongbwalu zones of Ituri province, which are among the areas hardest hit by the virus. According to the military governor of Ituri, Maj. Gen. Gaby Kasongo Mulumba, the campaign prioritizes medical personnel because they are deeply involved in the response and particularly exposed to infection. The deployment aims to cover approximately 20,000 front-line workers across Ituri and North Kivu over a period of six to nine months, as reported by health officials.
Government figures show that the country has recorded 7,541 confirmed cases, including 3,639 deaths, while 1,823 people have recovered. The current epidemic is concentrated in Ituri province and stands as the deadliest of all past 17 Ebola outbreaks in the country. The World Health Organization reported that the spread continues under difficult conditions marked by insecurity, population displacement, health worker strikes, and intense population movements, placing the outbreak on track to surpass the 2014–2016 West Africa epidemic.
Scientific Context and Vaccine Trial Details
The rollout involves the Ervebo vaccine, which is licensed for use against Ebola virus disease caused by the Zaire strain—a different and more common type of virus than the one driving the current crisis. According to the World Health Organization, approximately 70,000 doses of Ervebo have been approved for use in Congo. Out of this total, about 50,000 doses are designated for front-line and health workers, while 20,000 doses are allocated for a clinical trial.
This clinical trial investigates whether the Ervebo vaccine provides protection against the Bundibugyo virus, which causes the ongoing outbreak and currently lacks any licensed vaccine or treatment. Health authorities noted that while Ervebo may offer some protection because the two viruses are related, its actual efficacy in preventing illness from the Bundibugyo strain remains under scientific study.
Challenges and Local Response
The vaccination campaign follows an earlier rollout last month in Kisangani, located in Tshopo province, which targeted 14 health zones across Tshopo, Bas-Uele, and Haut-Uele provinces. Health workers on the ground have expressed mixed views regarding repeat vaccinations. Dr. Jean Paul Uzele, a front-line worker vaccinated with Ervebo during the 10th Ebola outbreak, stated that it remains unclear whether a second vaccination is necessary, though he noted he would accept it if administered. Another health worker in Bunia, Dr. Jeannot Elua, described the vaccine as beneficial while noting that medical personnel face mandatory protocols given their occupational exposure.